Pharmacoepidemiologist
Epidemiology & Benefit-Risk, GPV, Sanofi
Dr. Lin Li is a pharmacoepidemiologist in Sanofi US, primarily providing support to vaccines, diabetes and cardiovascular therapy areas. She promotes new evidence generation by application of artificial intelligence to support Sanofi products. After Dr. Li received her PhD in Epidemiology from Boston University School of Public Health in 2012, she worked as a pharmacoepidemiologist for 4 years at the Boston Collaborative Drug Surveillance Program, Boston University. Her research focused on post-marketing drug safety in multiple therapeutic areas using large electronic healthcare databases (e.g., Clinical Practice Research Datalink, MarketScan). Thereafter Dr. Li worked as a NHLBI T32 postdoctoral research fellow in Department of Quantitative Health Sciences, University of Massachusetts Medical School. She completed her Transdisciplinary Training in Cardiovascular Research using Medicare claims data and the Minimum Data Set before she joined Sanofi in 2018.